CT lung screening cuts cancer mortality 51% in Japan
In a new large-scale trial of CT lung cancer screening, researchers are reporting...Read more on AuntMinnie.comRelated Reading: Mental illness may double need for CT lung screening MRI shows promise for lung cancer screening CT lung screening reduces cancer mortality in men by 26% CT screening program targets nuclear weapons workers CT lung screening may benefit racial minorities most (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 14, 2018 Category: Radiology Source Type: news

Patients With Lower-Stage Small-Cell Lung Cancer Do Better Patients With Lower-Stage Small-Cell Lung Cancer Do Better
Patients with stage I to II small-cell lung cancer (SCLC) treated with chemoradiotherapy have better outcome than those with stage III disease, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Cancer Incidence Rising Rapidly Around the World
More than 30,000 people around the world will be diagnosed with malignant mesothelioma cancer in 2018, according to the latest estimates by the International Agency for Research on Cancer. Almost 26,000 will die from the disease. The numbers on mesothelioma were part of a larger report that included 36 types of cancer. The research covered 185 countries throughout 20 regions. It was published in the November/December issue of CA: A Cancer Journal for Clinicians. An estimated 18.1 million new cancer cases and 9.6 million cancer deaths are expected in 2018, a significant rise from 2012, when the agency published its last stu...
Source: Asbestos and Mesothelioma News - December 13, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

First line immunotherapy combination fails to improve overall survival in lung cancer
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.(1) The combination of immune checkpoint inhibitors and chemotherapy has been successfully tested in different trials as first line therapy for (Source: World Pharma News)
Source: World Pharma News - December 13, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

First line immunotherapy combination fails to improve overall survival in lung cancer
(European Society for Medical Oncology) First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2018 Category: Cancer & Oncology Source Type: news

Alectinib-induced Reversible Grade IV Nephrotoxicity Alectinib-induced Reversible Grade IV Nephrotoxicity
This case underscores the potential of the tyrosine kinase inhibitor alectinib to cause severe grade 4 renal toxicity, which was reversible in this patient with metastatic lung cancer.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Longer Follow-Up Data Show Role of Osimertinib in NSCLC Treatment
The long-term results from an analysis of two phase II studies confirmed the role of osimertinib in the treatment of T790M mutation –positive advanced non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Lung cancer - the 10p vegetable to add to your shopping list to avoid symptoms
LUNG CANCER risk could be lowered by making some diet changes, and by giving up smoking, if you ’re a smoker. You could lower your chances of lung cancer symptoms, including coughs and chest pain, by eating more of this cheap vegetable. Are you at risk? (Source: Daily Express - Health)
Source: Daily Express - Health - December 11, 2018 Category: Consumer Health News Source Type: news

Bittersweet Ending to Asbestos Cleanup in Libby, Montana
The asbestos cleanup of Libby, Montana, is coming to a celebrated close. The U.S. Environmental Protection Agency will soon end the largest, longest-running asbestos cleanup project in American history. It’s a bittersweet ending to what is left behind. The 19-year, $600 million EPA Superfund project aimed to right the wrongs created by the shuttered W.R. Grace and Co. vermiculite mine. Once the lifeblood of the community, it also became a cold-hearted killer. Although the mine was closed almost 30 years ago, health officials have since documented more than 400 deaths linked to asbestos-related diseases such as mes...
Source: Asbestos and Mesothelioma News - December 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mental illness may double need for CT lung screening
U.S. patients with a mental health illness have a considerably higher smoking...Read more on AuntMinnie.comRelated Reading: MRI shows promise for lung cancer screening CT lung cancer screening foiled by low adherence CT lung screening reduces cancer mortality in men by 26% Access to CT lung screening varies by population density CT lung screening may benefit racial minorities most (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 11, 2018 Category: Radiology Source Type: news

Advanced MRI better option for brain tumor recurrence
Is PET or MRI better for detecting tumor recurrence in patients with brain...Read more on AuntMinnie.comRelated Reading: DWI-MRI may be best for indeterminate lung nodules How effective is PET/MRI for rectal cancer? MRI shows promise for lung cancer screening Can whole-body MRI be used in oncologic staging? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 11, 2018 Category: Radiology Source Type: news

Can Staging for Lung Cancer Better Guide Treatment Decisions?
Researchers found that patients with stage I/II lung cancer have relatively long-term survival when treated with chemoradiotherapy, calling into question the practice of combining these patients with stage III patients. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Canadian guidelines recommend against early mammography
The Canadian Task Force on Preventive Health Care has released breast cancer...Read more on AuntMinnie.comRelated Reading: Canadian task force shifts gears on AAA screening Canadian guidelines support CT lung cancer screening Response: Canadian breast cancer guidelines rely on faulty data Canadian task force advises less frequent breast screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 10, 2018 Category: Radiology Source Type: news

Atezolizumab Now Also Approved for Front-Line NSCLC Atezolizumab Now Also Approved for Front-Line NSCLC
The immunotherapy has received FDA approval for an expanded indication for use in combination in nonsmall cell lung cancer.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Calling the Shots?
The USA has the highest drug costs in the world, and they are increasing at the fastest rate too. With one in five Americans saying they have been forced to leave a prescription unfilled due to high costs, the situation is clearly unsustainable.Payers and pharmacy benefit managers (PBMs), themselves facing increased criticism for blocking access to important medicines, are taking action by demanding that pharma companies justify the cost – and value – of their new medicines.“There is a point where a government, an employer or a healthcare plan has a finite amount of resources to spend,” says Brian H...
Source: EyeForPharma - December 10, 2018 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news

MD Anderson study shows key enzyme linked to therapy resistance in deadly lung cancer
(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). They believe two existing therapies may hold promise for clinical studies for this deadly and common lung cancer for which relapse often occurs within one year following treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2018 Category: Cancer & Oncology Source Type: news

Roche wins key lung cancer combo approval
Roche Holding ’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 7, 2018 Category: Pharmaceuticals Source Type: news

Ask Well: Do Cruciferous Vegetables Really Fight Cancer?
You cannot go wrong incorporating a lot of cruciferous vegetables, which include broccoli and brussels sprouts as well as dark leafy greens like kale and arugula, in your diet. (Source: NYT Health)
Source: NYT Health - December 7, 2018 Category: Consumer Health News Authors: RONI CARYN RABIN Tags: Vegetables Head and Neck Cancer Colon and Colorectal Cancer Lung Cancer Breast Cancer Diet and Nutrition Vitamins Dietary Supplements and Herbal Remedies Throat Prostate Gland Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - December 7, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2018 Category: Pharmaceuticals Source Type: news

Roche's lung cancer combo treatment wins FDA approval
Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Survival With Second Cancer After Stem Cell Transplant Tied to Cancer Type Survival With Second Cancer After Stem Cell Transplant Tied to Cancer Type
The outcome of second solid cancers following hematopoietic stem cell transplantation (HSCT) is strongly related to cancer type, with pancreatic and lung cancer being among those with the poorest outcome, according to European researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Chugai Receives Orphan Drug Designation for TECENTRIQ ® in Small cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors
(Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

AbbVie halts late-stage trial for lung cancer drug Rova-T
AbbVie said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA gives Roche immunotherapy drug priority review
The FDA has awarded Roche an accelerated review of its immunotherapy drug, Tecentriq, to treat non small-cell lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 5, 2018 Category: Pharmaceuticals Source Type: news

GRAIL ’s SUMMIT Will Help Define its Liquid Biopsy Path
A long-awaited and massive study with major implications for the liquid biopsy market is slated to start next year. Earlier this week, GRAIL revealed that it would initiate its 50,000-patient SUMMIT study in early 2019. Ages of the patients will be men and women between the ages of 50 and 77 who do not have a cancer diagnosis at the time of enrollment. The Menlo Park, CA-based company gave more specifics of the trial and said half the participants will be people at high risk for lung and other cancers due to a significant smoking history, and the other half will be people who are not at high risk for cancer based on smokin...
Source: MDDI - December 5, 2018 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news

Lung cancer symptoms: Eight signs not usually associated with the deadly disease
LUNG cancer symptoms can easily mistaken for less serious health conditions, which is why the disease often isn ’t diagnosed until it’s reached later stages. Here are seven signs often overlooked or ignored. (Source: Daily Express - Health)
Source: Daily Express - Health - December 5, 2018 Category: Consumer Health News Source Type: news

Lung cancer symptoms: Eight signs of the disease that are often ignored
LUNG cancer symptoms can easily mistaken for less serious health conditions, which is why the disease often isn ’t diagnosed until it’s reached later stages. Here are seven signs often overlooked or ignored. (Source: Daily Express - Health)
Source: Daily Express - Health - December 5, 2018 Category: Consumer Health News Source Type: news

Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer
Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals' revenues. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

Early Screening Key to Reducing Lung Cancer Deaths
Radiation oncologist Dr. Andrea McKee believes deaths from lung cancer — including those related to asbestos exposure — could be reduced significantly by increased utilization of early CT screening. McKee, chair of radiation oncology at Lahey Hospital and Medical Center in Burlington, Maine, has been a strong proponent of early screening for several years. “We could be saving tens of thousands of lives every year with this,” McKee told The Mesothelioma Center at Asbestos.com. “There is nothing else like it. The life-saving potential is the most important thing that has happened to cancer in my...
Source: Asbestos and Mesothelioma News - December 4, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Lung cancer symptoms: Six signs the disease is advanced and has spread outside the lungs
LUNG cancer symptoms don ’t tend to show until the tumour in the lungs has grown. But sometimes, when the disease has advanced and spread outside the lungs, a host of symptoms not related to the chest may be the first to show. Here are six to watch out for. (Source: Daily Express - Health)
Source: Daily Express - Health - December 3, 2018 Category: Consumer Health News Source Type: news

Lung cancer symptoms: Six signs the disease is advanced and spread outside the lungs
LUNG cancer symptoms don ’t tend to show until the tumour in the lungs has grown. But sometimes, when the disease has advanced and spread outside the lungs, a host of symptoms not related to the chest may be the first to show. Here are six to watch out for. (Source: Daily Express - Health)
Source: Daily Express - Health - December 3, 2018 Category: Consumer Health News Source Type: news

Lung cancer symptoms: Six signs the disease has advanced and spread outside the lungs
LUNG cancer symptoms don ’t tend to show until the tumour in the lungs has grown. But sometimes, when the disease has advanced and spread outside the lungs, a host of symptoms not related to the chest may be the first to show. Here are six to watch out for. (Source: Daily Express - Health)
Source: Daily Express - Health - December 3, 2018 Category: Consumer Health News Source Type: news

DWI-MRI may be best for indeterminate lung nodules
Diffusion-weighted MRI (DWI-MRI) offers comparable or even superior diagnostic...Read more on AuntMinnie.comRelated Reading: MRI shows promise for lung cancer screening FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2018 Category: Radiology Source Type: news

Trying to quit smoking? Acupuncture can help
(Natural News) Smoking does nothing good to the body. In fact, it’s a leading cause of disease and disability for almost every organ in the body. It increases the risk of multiple cancers, such as that of the lungs, mouth, throat, stomach, liver, and kidneys. At least 90 percent of lung cancer cases, in particular,... (Source: NaturalNews.com)
Source: NaturalNews.com - December 3, 2018 Category: Consumer Health News Source Type: news

CNIO and Hospital 12 de Octubre extend effectiveness of immunotherapy to more lung cancer patients
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients.Squamous cell carcinoma represents 20 percent to 30 percent of all cases of lung cancer and has a worse prognosis than other variants. It has the least amount of progress in terms of treatment.Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2018 Category: International Medicine & Public Health Source Type: news

Lung cancer symptoms: Three signs you’d never usually associate with the disease
LUNG cancer symptoms usually aren ’t obvious until the later stages of the disease, and can be mistaken for less serious health conditions. There are three to watch out for that you wouldn’t usually associate with the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - December 2, 2018 Category: Consumer Health News Source Type: news

Inherited Lung Cancer Syndromes Targeting Never Smokers Inherited Lung Cancer Syndromes Targeting Never Smokers
Which germline mutations are associated with inherited lung cancer syndromes in never smokers?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Biocartis partners with AstraZeneca on lung cancer diagnostics
Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb join forces
(Cancer Research UK) A 'rule book' to guide precision combination immunotherapies and to speed up the development of new lung cancer treatments will be created as part of a collaboration between Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb, announced today (Friday). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 29, 2018 Category: Cancer & Oncology Source Type: news

Nurse in Cancer Hoax Gets 2 Years in Prison for Theft Nurse in Cancer Hoax Gets 2 Years in Prison for Theft
A former Ohio State University nurse anesthetist told coworkers and her employer that she had metastatic lung cancer and bilked thousands of dollars from them.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lung cancer symptoms: This feeling in your chest could be tell-tale sign of the disease
LUNG cancer symptoms can be difficult to detect in the early stages as they usually don ’t become apparent until the tumour has grown. But one sign to be wary of is if your chest feeling a particular way. (Source: Daily Express - Health)
Source: Daily Express - Health - November 28, 2018 Category: Consumer Health News Source Type: news

Bristol-Myers Squibb Says Cancer Drug Combination Fails Late-Stage Trial Bristol-Myers Squibb Says Cancer Drug Combination Fails Late-Stage Trial
Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

How to live longer - the one fruit you should eat every day to prevent lung cancer
HOW to live longer: You could avoid an early death by eating a healthy, balanced diet, and by doing regular exercise. You could lower your risk of deadly lung cancer symptoms by adding this cheap fruit to your daily routine. (Source: Daily Express - Health)
Source: Daily Express - Health - November 27, 2018 Category: Consumer Health News Source Type: news

Nurse specialists ‘pivotal’ in improving lung cancer care
Too many lung cancer patients in the UK are missing out on “pivotal” support from a clinical nurse specialist, experts have warned. (Source: Nursing Times)
Source: Nursing Times - November 27, 2018 Category: Nursing Source Type: news

Health Tip: Identifying Lung Cancer Risks For Non Smokers
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 27, 2018 Category: Cancer & Oncology Tags: Oncology, FYI, Source Type: news